Erlotinib/gefitinibHair and scalp changes: 13 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2013年 / 1470卷 / 1期

关键词：

D O I：

10.1007/s40278-013-5977-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：21 / 21

相关论文

共 50 条

[41] NatalizumabErythroblastaemia: 13 case reports
Reactions Weekly, 2018, 1687 (1) : 165 - 165
[42] ImmunotherapiesDRESS: 13 case reports
Reactions Weekly, 2023, 1986 (1) : 211 - 211
[43] ImmunosuppressantsInfections: 13 case reports
Reactions Weekly, 2022, 1934 (1) : 232 - 232
[44] NimesulideHepatotoxicity: 13 case reports
Reactions Weekly, 2011, 1350 (1) : 35 - 35
[45] DenosumabHypocalcaemia: 13 case reports
Reactions Weekly, 2015, 1580 (1) : 137 - 137
[46] CapsaicinPain: 13 case reports
Reactions Weekly, 2015, 1538 (1) : 58 - 58
[47] RisperidoneHyperprolactinaemia: 13 case reports
Reactions Weekly, 2015, 1542 (1) : 195 - 195
[48] Bevacizumab/erlotinib/gefitinibInterstitial lung disease: 5 case reports
Reactions Weekly, 2017, 1653 (1) : 74 - 74
[49] AntineoplasticsThrombocytopenia: 13 case reports
Reactions Weekly, 2016, 1583 (1) : 119 - 119
[50] Afatinib/erlotinib/gefitinibAcquired drug resistance: 2 case reports
Reactions Weekly, 2018, 1696 (1) : 18 - 18

← 1 2 3 4 5 →